Overview

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

Status:
NOT_YET_RECRUITING
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and early effectiveness of the NaviFUS system with concomitant microbubble administration in conjunction with BEV in recurrent GBM patients.
Phase:
NA
Details
Lead Sponsor:
University of Cincinnati
Collaborator:
NaviFUS Corporation
Treatments:
Bevacizumab